Enrolment in the AXESS first-in-human (FIH) trial of Xeltis’ restorative hemodialysis vascular access graft, aXess, has been completed, with 20 patients successfully implanted. Very promising preliminary efficacy and safety results from one of the participating centers will be presented [...]
On World Heart Day, we renew Xeltis’ pledge to make the difference for patients with heart disease. Cardiovascular disease can be controlled, treated and improved but it is with a patient day in, day out. Likewise, we work day in, [...]
Substantial progress across Xeltis’ restorative cardiovascular device platform will be illustrated in two presentations at the International Society for Applied Cardiovascular Biology (ISACB) 2022 meeting this week. Xeltis CTO, Martijn Cox, will present the advancements of clinical trials on [...]
The Chinese company Grand Pharmaceutical Group Ltd (0512.HK) has committed to invest €15 million in equity and license fees, as a cornerstone funding for Xeltis ongoing Series D2 financing round. The Grand Pharma commitment comprises an equity investment and [...]
Xeltis BV is looking for a skilled and driven Clinical Specialist to work in its enthusiastic team, sustaining the clinical realization of Xeltis’ revolutionary restorative medical devices. Xeltis is a clinical stage medical device company with the world’s most [...]
For first-hand experience with Xeltis restorative hemodialysis vascular access device aXess, there is a very insightful article by Doctor Jan De Letter in the latest issue of AZ Link magazine. Dr De Letter is a vascular surgeon at AZ [...]
Xeltis hired Dr Paulo Neves as Vice President for Clinical and Medical Affairs. Paulo brings to Xeltis remarkable medical experience as a practicing cardiac surgeon and pioneering implanter of a number of cardiovascular medical devices, along with medical lead [...]
Results from novel imaging analysis of the Endogenous Tissue Restoration (ETR) process in Xeltis’ devices further advance the understanding of in vivo polymer absorption and neotissue formation. The outcomes have been obtained using a novel, non-invasive, laser-based imaging method [...]
CEO Eliane Schutte shared how Xeltis restorative devices can help combine clinical needs with a patient-centric approach in cardiovascular treatment. Speaking today at LSX World Congress 2022 in London, Eliane explained how the most advanced polymer-based restorative devices may offer [...]
Preliminary results from a clinical trial of Xeltis’ restorative hemodialysis access graft, aXess, showed very promising early puncturing, functional patency and safety data. The data, from the ongoing first-in-human aXess trial, will be presented at CX 2022, the Charing [...]
